Cited by 74Sexual Differentiation and DisordersAdrenal Hormones and DisordersOvarian function and disorders

Modified release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia

Open access
Jones, Christopher M., Mallappa, Ashwini, Reisch, Nicole, Nikolaou, Nikolaos, Krone, Nils, Hughes, Beverly A., O’Neil, Donna M., Whitaker, Martin J. +5 more·2016·The Journal of Clinical Endocrinology & Metabolism

Abstract

Context: The classic androgen synthesis pathway proceeds via dehydroepiandrosterone, androstenedione, and testosterone to 5α-dihydrotestosterone. However, 5α-dihydrotestosterone synthesis can also be achieved by an alternative pathway originating from 17α-hydroxyprogesterone (17OHP), which accumulates in congenital adrenal hyperplasia (CAH). Similarly, recent work has highlighted androstenedione-derived 11-oxygenated 19-carbon steroids as active androgens, and in CAH, androstenedione is generated directly from 17OHP. The exact contribution of alternative pathway activity to androgen excess in CAH and its response to glucocorticoid (GC) therapy is unknown. Objective: We sought to quantify classic and alternative pathway-mediated androgen synthesis in CAH, their diurnal variation, and their response to conventional GC therapy and modified-release hydrocortisone. Methods: We used urinary steroid metabolome profiling by gas chromatography-mass spectrometry for 24-hour steroid excretion analysis, studying the impact of conventional GCs (hydrocortisone, prednisolone, and dexamethasone) in 55 adults with CAH and 60 controls. We studied diurnal variation in steroid excretion by comparing 8-hourly collections (23:00-7:00, 7:00-15:00, and 15:00-23:00) in 16 patients with CAH taking conventional GCs and during 6 months of treatment with modified-release hydrocortisone, Chronocort. Results: Patients with CAH taking conventional GCs showed low excretion of classic pathway androgen metabolites but excess excretion of the alternative pathway signature metabolites 3α,5α-17-hydroxypregnanolone and 11β-hydroxyandrosterone. Chronocort reduced 17OHP and alternative pathway metabolite excretion to near-normal levels more consistently than other GC preparations. Conclusions: Alternative pathway-mediated androgen synthesis significantly contributes to androgen excess in CAH. Chronocort therapy appears superior to conventional GC therapy in controlling androgen synthesis via alternative pathways through attenuation of their major substrate, 17OHP.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2016-2855

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In summary, androgens are generated in CAH patients via all three major pathways.

    “In summary, androgens are generated in CAH patients via all three major pathways (132).”
  • 11-oxygenated C19 steroids have been shown to be increased in CAH due to 2OH deficiency.

    “11-oxygenated C19 steroids have been shown to be increased in CAH due to 2OH deficiency 130,131”

    From Congenital adrenal hyperplasia (2017) · cites this paper as [130]

  • Exaggerated activity of both backdoor and 11-oxygenated C19 pathways persists in treated patients, even if the classic androgen pathway activity is downregulated.

    “exaggerated activity of both backdoor and 11-oxygenated C19 pathways persists in treated patients, even if the classic androgen pathway activity is downregulated.130”

    From Congenital adrenal hyperplasia (2017) · cites this paper as [130]

  • Urinary 11-oxygenated ETIO is predominantly a product of glucocorticoid metabolism, while urinary 11-oxygenated AST results mainly from 11-oxygenated androgens.

    “While urinary 11-oxygenated ETIO is predominantly a product of glucocorticoid metabolism, urinary 11-oxygenated AST results mainly from 11-oxygenated androgens (Jones et al., 2016, Shackleton et al., 2008).”

    From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as Jones et al., 2016

  • Urinary 11-oxygenated AST and 11-oxygenated ETIO originate from androgen and glucocorticoid metabolism, however in different ratios.

    “Urinary 11-oxygenated AST and 11-oxygenated ETIO originate from androgen and glucocorticoid metabolism, however in different ratios.”

    From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as Jones et al., 2016

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 27 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Jones, C. M., Mallappa, A., Reisch, N., Nikolaou, N., Krone, N., Hughes, B. A., O’Neil, D. M., Whitaker, M. J., Tomlinson, J. W., Storbeck, K.-H., Merke, D. P., Ross, R. J., & Arlt, W.
Affiliations
  • University of Birmingham (GB)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
  • Ludwig-Maximilians-Universität München (DE)
  • University of Oxford (GB)
  • Diurnal (United Kingdom) (GB)
  • Stellenbosch University (ZA)
Corresponding author
Arlt, Wiebke
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2016-11-15
Volume
102
Issue
6
Pages
jc.2016-2855
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2556069495
Cited by
74
References
27
Citations by year
2026: 4 · 2025: 6 · 2024: 12 · 2023: 6 · 2022: 7 · 2021: 3 · 2020: 8 · 2019: 8 · 2018: 13 · 2017: 6 · 2016: 1
FWCI
4.85
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
Funders
  • National Institute for Health and Care Research (ACF-2015-02-004)
  • Royal Society
  • Academy of Medical Sciences (NAF004\1002)
  • European Commission (281654)
  • National Institutes of Health
  • Medical Research Council (MR/P011462/1, 0900567)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
Keywords
congenital adrenal hyperplasia, modified-release hydrocortisone, glucocorticoid therapy, 17-hydroxyprogesterone, hyperandrogenism, prednisolone, dexamethasone
MeSH terms
Adolescent, Adrenal Hyperplasia, Congenital, Adult, Androgens, Androsterone, Circadian Rhythm, Cortodoxone, Delayed-Action Preparations, Dexamethasone, Female, Glucocorticoids, Humans, Hydrocortisone, 17-alpha-Hydroxypregnenolone, Male, Gas Chromatography-Mass Spectrometry, Middle Aged, Prednisolone, Pregnanetriol, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review